Posted: Monday, December 4, 2023
The diagnosis and surveillance of patients with upper tract urothelial carcinoma may possibly be regulated through the use of blood-based liquid biopsy biomarkers, according to a study presented at the 2023 Society of Urologic Oncology (SUO) Annual Meeting (Poster 47). However, additional investigative efforts are warranted to determine the extent of efficacy of this novel clinical modality, suggested Alireza Ghoreifi, MD, of the University of Southern California Institute of Urology, Los Angeles, and colleagues.
A total of 28 patients with upper tract urothelial carcinoma were recruited for the study. Peripheral blood samples were collected before surgical intervention with curative intent and after surgical intervention. Patient samples underwent various analytic tests to detect circulating tumor cells and oncosomes. Presurgical samples were subsequently compared with samples from healthy blood donors (n = 50) and postoperative samples (n = 21).
The study findings revealed significant differences in the detection of rare analytes in preoperative samples compared with samples obtained from healthy blood donors. Differences in the analytes detected in preoperative samples included total oncosomes, D|V cells, D|CK|V|CD cells, total CVK cells, CK oncosomes, D|V|CD cells, CK|CD oncosomes, and D-alone cells. When preoperative and postoperative samples were compared, the presence of total, CK, and CK|V oncosomes was significantly decreased in the postoperative samples. This trend was similarly observed for the levels of D, D|V, and D|V|CD cells. Moreover, the rate of progression-free survival was worse in patients who had a positive preoperative CK|V LEV.
Disclosure: No information regarding conflicts of interest was provided.